+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Myelofibrosis Therapeutics Market 2018-2022 - Product Image

Global Myelofibrosis Therapeutics Market 2018-2022

  • ID: 4745550
  • Report
  • December 2018
  • Region: Global
  • 106 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • CELGENE
  • Incyte
  • Novartis
  • MORE
Myelofibrosis is as Philadelphia chromosome- negative myeloproliferative neoplasm (MPN), a rare mutation. The only FDA approved drug therapy is JAKAVI/JAKAFI (Ruxolitinib). It is a potent oral JAK1/ JAK2 inhibitor used for treating the patients with myelofibrosis. HSCT therapy is also having disadvantages regarding the unavailability of matching donors. Other therapies, including the transfusion and androgen therapy, merely reduce the anemic side effects of myelofibrosis. Thus, among all treatments available at present, none can be considered as an ideal one that can completely help in eradicating the disease. Analysts have predicted that the myelofibrosis therapeutics market will register a CAGR of more than 7% by 2022.

Market Overview

Increasing number of companies entering the myelofibrosis segment

Before the launch of JAKAVI/JAKAFI, there were very few companies investing in the R&D of myelofibrosis therapies.

Limited market size as myelofibrosis is a rare disorder

The number of available therapies including the orphan drugs for this disorder is very limited. The treatment options employed by physicians are mostly the off- label drugs that are meant for the treatment of some other condition or the blood transfusion or stem cell transplantation.

For the detailed list of factors that will drive and challenge the growth of the myelofibrosis therapeutics market during the 2018-2022, view this report.

Competitive Landscape

The global myelofibrosis therapeutics market is extremely concentrated. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • CELGENE
  • Incyte
  • Novartis
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 05: PIPELINE ANALYSIS
  • Pipeline analysis
PART 06: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 08: MARKET SEGMENTATION BY TYPE OF TREATMENT
  • Segmentation by type of treatment
  • Comparison by type of treatment
  • Drug therapy - Market size and forecast 2017-2022
  • Blood transfusion - Market size and forecast 2017-2022
  • HSCT - Market size and forecast 2017-2022
  • Androgen Therapy - Market size and forecast 2017-2022
  • Market opportunity by type of treatment
PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity
PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 13: MARKET TRENDS
  • HSCT is the only curative option for myelofibrosis
  • High off-label prescription including hydroxyurea, Immunomodulators, and steroids
PART 14: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 15: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb
  • CELGENE
  • Incyte
  • Novartis
PART 16: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Global oncology therapeutics market
Exhibit 02: Global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline molecules for myelofibrosis 2017-2018
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global - Market size and forecast 2017-2022 ($ mn)
Exhibit 10: Global - Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2017
Exhibit 19: Type of treatment - Market share 2017-2022 (%)
Exhibit 20: Comparison by type of treatment
Exhibit 21: Drug therapy - Market size and forecast 2017-2022 ($ mn)
Exhibit 22: JAKAVI/JAKAFI sales from 2015-2017
Exhibit 23: Drug therapy - Year-over-year growth 2018-2022 (%)
Exhibit 24: Blood transfusion - Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Blood transfusion - Year-over-year growth 2018-2022 (%)
Exhibit 26: HSCT - Market size and forecast 2017-2022 ($ mn)
Exhibit 27: HSCT - Year-over-year growth 2018-2022 (%)
Exhibit 28: Androgen therapy - Market size and forecast 2017-2022 ($ mn)
Exhibit 29: Androgen Therapy - Year-over-year growth 2018-2022 (%)
Exhibit 30: Market opportunity by type of treatment
Exhibit 31: Customer landscape
Exhibit 32: Global - Market share by geography 2017-2022 (%)
Exhibit 33: Regional comparison
Exhibit 34: Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 35: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 36: Top 3 countries in Americas
Exhibit 37: EMEA - Market size and forecast 2017-2022 ($ mn)
Exhibit 38: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 39: Top 3 countries in EMEA
Exhibit 40: APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 41: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 42: Top 3 countries in APAC
Exhibit 43: Market opportunity
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Bristol-Myers Squibb - Overview
Exhibit 49: Bristol-Myers Squibb - Business segments
Exhibit 50: Bristol-Myers Squibb - Organizational developments
Exhibit 51: Bristol-Myers Squibb - Geographic focus
Exhibit 52: Bristol-Myers Squibb - Key offerings
Exhibit 53: Bristol-Myers Squibb - Key customers
Exhibit 54: CELGENE - Overview
Exhibit 55: CELGENE - Business segments
Exhibit 56: CELGENE - Organizational developments
Exhibit 57: CELGENE - Geographic focus
Exhibit 58: CELGENE - Key offerings
Exhibit 59: CELGENE - Key customers
Exhibit 60: Incyte - Overview
Exhibit 61: Incyte - Business segments
Exhibit 62: Incyte - Organizational developments
Exhibit 63: Incyte - Geographic focus
Exhibit 64: Incyte - Key offerings
Exhibit 65: Incyte - Key customers
Exhibit 66: Novartis - Overview
Exhibit 67: Novartis - Business segments
Exhibit 68: Novartis - Organizational developments
Exhibit 69: Novartis - Geographic focus
Exhibit 70: Novartis - Segment focus
Exhibit 71: Novartis - Key offerings
Exhibit 72: Novartis - Key customers
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • CELGENE
  • Incyte
  • Novartis
  • MORE
Global Myelofibrosis Therapeutics Market 2018-2022

The analyst recognizes the following companies as the key players in the global myelofibrosis therapeutics market: Bristol-Myers Squibb, CELGENE, Incyte, Novartis.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the high off-label prescription including hydroxyurea, Immunomodulators and steroids.”

According to the report, one of the major drivers for this market is the increasing number of companies entering the myelofibrosis segment.

Further, the report states that one of the major factors hindering the growth of this market is the undefined etiology and unidentified cause of disease progression.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Bristol-Myers Squibb
  • CELGENE
  • Incyte
  • Novartis
Note: Product cover images may vary from those shown
Adroll
adroll